EUVIMEDEUVIMED entdecken
Übersichtsarbeit

A Pathologist’s Guide to Non-clinical Safety Assessment of Adoptive Cell Therapy Products

Alessandra Piersigilli, Vinicius S Carreira, Frédéric Gervais, Keith Mansfield, Brian E McIntosh, Ingrid Cornax iD

Toxicologic Pathology · 2024-12 · 52 (8) · 531-544

DOI: 10.1177/01926233241298570 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Toxicologic Pathology, online erschienen am 06.12.2024. Verfasst von Alessandra Piersigilli und 5 weiteren Autor:innen. Beteiligte Einrichtung: Takeda Development Center Americas, Cambridge, MA, USA. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 96 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Through two decades of research and development, adoptive cell therapies (ACTs) have revolutionized treatment for hematologic malignancies. Many of the seven US Food and Drug Administration (FDA)-approved products are proven to be a curative last line of defense against said malignancies. The ACTs, known more commonly as chimeric antigen receptor (CAR) T-cells, utilize engineered lymphocytes to target and destroy cancer cells in a patient-specific, major histocompatibility complex (MHC)-independent manner, acting as “living drugs” that adapt to and surveil the body post-treatment. Despite their efficacy, CAR T-cell therapies present unique challenges in preclinical safety assessment. The safety and pharmacokinetics of CAR T-cells are influenced by numerous factors including donor and recipient characteristics, product design, and manufacturing processes that are not well-predicted by existing in vitro and in vivo preclinical safety models. The CAR therapy-mediated toxicities in clinical settings primarily arise from unintended targeting of non-tumor cells, potential tumorigenicity, and severe immune activation syndromes like cytokine release syndrome and immune effector cell-associated neurotoxicity. Addressing these issues necessitates a deep understanding of CAR target expression in normal tissues, inclusive of the spatial microanatomical distribution, off-target screening, and a deep understanding CAR cell manufacturing practices and immunopathology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunotherapy, AdoptiveHumansAnimalsReceptors, Chimeric AntigenPathologists

Stichwörter der Autor:innen

adoptive cell therapycytokine release syndromeimmune cell activation neurotoxicity syndrome (ICANS)off-target toxicityoff-tumor toxicitytissue microarray

Substanzen

Receptors, Chimeric Antigen

Autor:innen und Institutionen

  • Takeda Development Center Americas, Cambridge, MA, USA.
  • Johnson & Johnson Innovative Medicine, San Diego, CA, USA.
  • Charles River Laboratories, Evreux, France.
  • Novartis, Cambridge, MA, USA.
  • Labcorp, Madison, WI, USA.
  • Altos Labs, Redwood City, CA, USA.

ORCID-Profile: Ingrid Cornax

Zitieren

APA

Piersigilli, A., Carreira, V. S., Gervais, F., Mansfield, K., McIntosh, B. E., & Cornax, I. (2024). A Pathologist’s Guide to Non-clinical Safety Assessment of Adoptive Cell Therapy Products. Toxicologic Pathology, 52(8), 531-544. https://doi.org/10.1177/01926233241298570

Vancouver

Piersigilli A, Carreira VS, Gervais F, Mansfield K, McIntosh BE, Cornax I. A Pathologist’s Guide to Non-clinical Safety Assessment of Adoptive Cell Therapy Products. Toxicologic Pathology. 2024;52(8):531-544. doi:10.1177/01926233241298570

BibTeX
@article{Piersigilli2024,
  author = {Piersigilli, Alessandra and Carreira, Vinicius S and Gervais, Frédéric and Mansfield, Keith and McIntosh, Brian E and Cornax, Ingrid},
  title = {A Pathologist’s Guide to Non-clinical Safety Assessment of Adoptive Cell Therapy Products},
  journal = {Toxicologic Pathology},
  year = {2024},
  volume = {52},
  number = {8},
  pages = {531--544},
  doi = {10.1177/01926233241298570}
}
Kostenlos starten →